The concern of generic rivalry has long loomed over copyright’s blockbuster drug, PDE5 Inhibitor, triggering questions about the outlook of similar pharmaceutical stakes. While initial years saw significant gains, the exclusivity expiration has opened the way for cheaper copies, likely reducing revenue and posing a significant hazard for stakehol